Identification of epigenetic alterations and novel pathways seen with the transformed phenotypes (such as FGFR for EMT or AURKA for RB1-deficient, transformed SCLC) can help develop novel therapies. The gene discussed is AURKA; the disease is small cell lung carcinoma.